参松养心胶囊预防持续性房颤消融术后房性快速心律失常:SS-AFRF试验
SS-AFRF试验为多中心、随机、双盲、安慰剂对照研究,纳入920例首次接受射频导管消融的持续性房颤患者,随机给予参松养心胶囊(1.6g每日三次)或安慰剂治疗12个月。
要点
- 参松养心组12个月生活质量评分优于安慰剂组,严重不良事件无显著差异。
核心结论
- 持续性房颤射频导管消融术后使用参松养心胶囊可减少房性快速心律失常复发,并改善生活质量。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照临床试验,在中国66个中心纳入920例首次接受消融的持续性房颤患者。
- 主要终点为3个月空白期后持续≥30秒的复发性房性快速心律失常,采用意向性治疗分析。
主要发现
- 参松养心组12个月生活质量评分优于安慰剂组。
- 两组严重不良事件发生率无显著差异。
关键数值与推荐
- 主要终点事件定义:空白期3个月后持续≥30秒的复发性房性快速心律失常。
临床怎么用
- 对于首次接受射频导管消融的持续性房颤患者,可考虑在术后加用参松养心胶囊以降低房性快速心律失常复发风险。
- 参松养心胶囊可能改善术后12个月的生活质量,且严重不良事件未见增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Despite advances in technology and techniques, the recurrence rate of persistent atrial fibrillation (AF) following catheter ablation remains high. The Shensong Yangxin (SSYX) capsule, a renowned traditional Chinese medicine formula, is used in the treatment of cardiac arrhythmias. This trial aimed to investigate whether the SSYX can improve clinical outcomes in patients who have undergone catheter ablation for persistent AF. METHODS: A multi-centre, randomized, double-blind, placebo-controlled clinical trial was conducted at 66 centres in China among 920 patients with persistent AF undergoing first ablation. Participants were randomized to oral SSYX, 1.6 g (.4 g/granule) thrice daily (n = 460), or matched placebo (n = 460) for 12 months. The primary endpoint was recurrent atrial tachyarrhythmias lasting for ≥30 s following a blanking period of 3 months. Secondary endpoints included time to first documented atrial tachyarrhythmias, AF burden, cardioversion, stroke/systemic embolism, changes in echocardiographic parameters, and quality-of-life (QoL) score. Analyses were performed according to the intention-to-treat principle. RESULTS: A total of 920 patients underwent randomization (460 assigned to SSYX group and 460 assigned to placebo group). During the follow-up of 12 months, patients assigned to SSYX had a higher event-free rate from recurrent atrial tachyarrhythmias when compared with the placebo group (12-month Kaplan-Meier event-free rate estimates, 85.5% and 77.7%, respectively; hazard ratio, .6; 95% confidence interval .4-.8; P = .001). Patients assigned to receive SSYX had a better QoL score at 12 months compared to those randomized to placebo. There was no significant difference in the incidence of serious adverse events between the two groups. CONCLUSIONS: Treatment with SSYX following radiofrequency catheter ablation for persistent AF reduced the incidence of recurrent atrial tachyarrhythmias and led to clinically significant improvements in QoL during a 12-month follow-up in a Chinese population.
引用
- Huang, Liu, Shuai, et al. Atrial tachyarrhythmia prevention by Shensong Yangxin after catheter ablation for persistent atrial fibrillation: the SS-AFRF trial. Eur Heart J. 2024. PMID: 39178138. doi:10.1093/eurheartj/ehae532
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。